FLUCORT 0.025%W/W GEL

Indications

• Eczema
• Psoriasis
• Contact dermatitis
• Allergic dermatitis
• Seborrheic dermatitis

Dosage

Children: Refer to specific product information or clinical guidelines for appropriate dosing in children, as it varies by formulation and condition treated.

Adults: Refer to specific product information or clinical guidelines for appropriate dosing, as it varies by formulation and condition treated.

Mechanism of action

Acetonide exerts its effects by binding to glucocorticoid receptors in the cytoplasm of target cells, leading to the translocation of the receptor-ligand complex into the nucleus. This complex then influences the expression of specific genes, resulting in decreased production of pro-inflammatory cytokines and increased production of anti-inflammatory proteins. This modulation of gene expression contributes to its anti-inflammatory and immunosuppressive effects.

Pharmacodynamics

The pharmacodynamics of acetonide involve its ability to inhibit the migration of leukocytes to sites of inflammation, reduce the production of inflammatory mediators such as prostaglandins and leukotrienes, and suppress the immune response. The potency and duration of action can vary based on the specific formulation and concentration used.

Pharmacokinetics

Acetonide is absorbed through the skin when applied topically, with systemic absorption depending on the formulation, application area, and duration of use. It undergoes hepatic metabolism, and its metabolites are excreted primarily through the urine. The half-life and clearance rates can vary based on individual patient factors and specific formulations.

Contra-indications

• Hypersensitivity to acetonide or any component of the formulation.
• Active or untreated infections at the site of application.

Adverse effects

• Local irritation or burning sensation at the application site.
• Skin thinning or atrophy with prolonged use.
• Systemic effects such as adrenal suppression with high doses or prolonged therapy.

Interactions

• Increased risk of systemic effects when used with other corticosteroids.
• Potentially altered metabolism when administered with CYP3A4 inhibitors or inducers.

Precautions

• Use with caution in patients with a history of tuberculosis or other infections.
• Monitor for signs of adrenal insufficiency in patients on high doses.
• Avoid application to large areas of the body or under occlusive dressings.

Pregnancy

Acetonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult with a healthcare professional before use.

Breast-feeding

Limited data available. Use with caution as it may be excreted in breast milk. Consult with a healthcare professional before use.

Storage

Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Topical cream
• Topical ointment
• Topical solution

Indications

• Eczema
• Psoriasis
• Dermatitis
• Allergic skin reactions
• Lichen planus

Dosage

Children: For paediatric patients, dosage should be determined by a healthcare professional, considering the child's age, weight, and the specific condition being treated. Refer to the BNF for Children for specific dosing guidelines.

Adults: The dosage of fluocinolone varies based on the formulation and severity of the condition. It is typically applied as a thin layer to the affected area once or twice daily, as directed by a healthcare professional.

Mechanism of action

Fluocinolone binds to specific corticosteroid receptors in the cytoplasm of target cells, leading to the transcription of anti-inflammatory proteins and the repression of pro-inflammatory cytokines. This process ultimately results in a decrease in inflammation and an alteration of the immune response.

Pharmacodynamics

Fluocinolone exhibits strong anti-inflammatory and immunosuppressive effects. Its potency allows for effective management of conditions characterized by excessive inflammation. The drug helps to decrease the migration of leukocytes to sites of inflammation and inhibits the release of inflammatory mediators, thereby alleviating symptoms associated with inflammatory skin disorders.

Pharmacokinetics

Fluocinolone is absorbed through the skin when applied topically. The systemic absorption may vary depending on the formulation, the area of application, and the condition of the skin. Once absorbed, fluocinolone is metabolized in the liver and excreted primarily via urine. The half-life of fluocinolone is variable, influenced by factors such as the route of administration and individual patient characteristics.

Adverse effects

• skin irritation
• burning sensation
• dryness
• hypopigmentation
• striae
• telangiectasia
• folliculitis

Precautions

• Avoid use on broken skin
• Consider potential systemic absorption especially in large areas or under occlusion
• Caution in patients with diabetes or impaired adrenal function

Pregnancy

Fluocinolone is classified as Category C. Its use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Fluocinolone is excreted in breast milk. Caution should be exercised when administering to nursing women, particularly on large areas of the skin.

Storage

Store below 25 degrees Celsius. Protect from light.

Formulations

• Topical cream
• Topical ointment
• Topical solution